Management Practice and Drug Related Problems and Its Contributing Factors Among Cervical Cancer Patients at Oncologic Center in Ethiopia: A Hospital-Based Retrospective Study

References

• World Health Organization. Fact sheet N°297 Reviewed January 2013; 2013.
   Google Scholar
• Denny L. The prevention of cervical cancer in developing countries. BJOG. 2005;112(9):1204–1212. doi:10.1111/j.1471-0528.2005.00713.x
   PubMed Web of Science ®Google Scholar
• Somi MH, Dolatkhah R, Sepahi S, Belalzadeh M, Naghashi S, Asghari Jafarabadi M. A 12-year trend analysis of the incidence of gastrointestinal cancers in East Azerbaijan: last updated results of an ongoing population-based cancer registry. BMC Cancer. 2019;19(1):782. doi:10.1186/s12885-019-6008-3
   PubMed Web of Science ®Google Scholar
• Cumbera SN, Nchanji KN, Tsoka-Gwegweni JM. Breast cancer among women in sub-Saharan Africa: prevalence and a situational analysis. South Afr J Gynaecol Oncol. 2017;9:35–37. doi:10.1080/20742835.2017.1391467
   Web of Science ®Google Scholar
• Federal Ministry of Health Ethiopia. National Cancer Control Plan 2016–2020. Available from: https://www.iccp-portal.org/sites/default/files/plans/CCP%20Ethiopia%20Final%20261015.pdf. Accessed June 18, 2020.
   Google Scholar
• Bulsink A, Imholz ALT, Brouwers JRB, Jansman FGA. Characteristics of potential drug-related problems among oncology patients. Int J Clin Pharm. 2013;35(3):401–407. doi:10.1007/s11096-012-9747-7
   PubMed Web of Science ®Google Scholar
• Munenu K, Pierre Y, Munogo LT, et al. The prevalence and patterns of drug related problems associated with anti retroviral drugs in the management of HIV/AIDS patients at Ndola Central Hospital in 2016. J Pharm. 2016;6:8–23.
   Google Scholar
• Iftikhar A, Jehanzeb K, Ullah A. Clinical pharmacy services in medical oncology unit, Peshawar, Pakistan. Pharmacologyonline. 2015;1:10–12.
   Google Scholar
• Nelson KM, Talbert RL. Drug-related hospital admissions. Pharmacotherapy. 1996;16(4):701–707.
   PubMed Web of Science ®Google Scholar
• Livingston PM, Craike M, Slavin M. Clinical and economic burden of emergency department presentations for neutropenia following outpatient chemotherapy for cancer in Victoria, Australia. Oncologist. 2012;17(7):998–1004. doi:10.1634/theoncologist.2011-0456
   PubMed Web of Science ®Google Scholar
• Ko Y, Gwee YS, Huang YC, Chiang J, Chan A. Costs and length of stay of drug-related hospital admissions in cancer patients. Clin Ther. 2014;36(4):588–592. doi:10.1016/j.clinthera.2014.02.014
   PubMed Web of Science ®Google Scholar
• Vantard N, Ranchon F, Schwiertz V, et al. EPICC study: evaluation of pharmaceutical intervention in cancer care. J Clin Pharm Ther. 2015;40(2):196–203. doi:10.1111/jcpt.12242
   PubMed Web of Science ®Google Scholar
• Stoll P, Kopittke L. Potential drug–drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study. Int J Clin Pharm. 2015;37(3):475–484. doi:10.1007/s11096-015-0083-6
   PubMed Web of Science ®Google Scholar
• Chopra D, Rehan H, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey. Indian J Med Paediatr Oncol. 2016;37(1):42. doi:10.4103/0971-5851.177015
   PubMed Web of Science ®Google Scholar
• Belachew SA, Erku DA, Mekuria AB, Gebresillassie BM. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a crosssectional study. Drug Healthc Patient Saf. 2016;8:83–90. doi:10.2147/DHPS.S116924
   PubMedGoogle Scholar
• Sisay EA, Engidawork E, Yesuf TA, Ketema EB. Drug related problems in chemotherapy of cancer patients. J Cancer Sci Ther. 2015;07(02):55–59.
   Google Scholar
• D’Amato S. Improving patient adherence with oral chemotherapy. Oncol Issues. 2008;23(4):42–45. doi:10.1080/10463356.2008.11884291
   Google Scholar
• Yeoh TT, Tay XY, Si P, Chew L. Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy. J Geriatr Oncol. 2015;6(4):280–287. doi:10.1016/j.jgo.2015.05.001
   PubMed Web of Science ®Google Scholar
• Parveen S, Sajjad R, Masood M, et al. Cervical cancer: outcome of treatment and causes of failure. JPMA. 2006;56(10):436.
   PubMedGoogle Scholar
• Holub K, Biete A. Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients. Clin Transl Oncol. 2019;21(7):836–844. doi:10.1007/s12094-018-1991-4
   PubMed Web of Science ®Google Scholar
• Degu A, Njogu P, Weru I, Karimi P. Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya. Gynecol Oncol Res Pract. 2017;4(1):15. doi:10.1186/s40661-017-0054-9
   PubMedGoogle Scholar
• Quinn BA, Deng X, Colton A, Bandyopadhyay D, Carter JS, Fields EC. Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival. Brachytherapy. 2019;18(1):29–37. doi:10.1016/j.brachy.2018.08.016
   PubMed Web of Science ®Google Scholar
• Liu YM, Ni LQ, Wang SS, Lv QL, Chen WJ, Ying SP. Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study. World J Surg Oncol. 2018;16(1):1–7. doi:10.1186/s12957-017-1307-0
   PubMed Web of Science ®Google Scholar
• Wassie M, Argaw Z, Tsige Y, Abebe M, Kisa S. Survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: a retrospective cohort study. BMC Cancer. 2019;19(1):1–11. doi:10.1186/s12885-019-6447-x
   PubMed Web of Science ®Google Scholar
• Lund JL, Sanoff HK, Hinton SP, Muss HB, Pate V, Stürmer T. Potential medication-related problems in older breast, colon, and lung cancer patients in the United States. Cancer Epidemiol Biomark Prev. 2018;27(1):41–49. doi:10.1158/1055-9965.EPI-17-0523
   PubMed Web of Science ®Google Scholar
• Organization WH. Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. International Agency for Research on Cancer. Geneva: World Health Organization; 2018.
   Google Scholar
• World Health Organization. Preventing Chronic Diseases: A Vital Investment. Geneva: World Health Organization; 2005.
   Google Scholar
• Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229–2232.
   PubMedGoogle Scholar
• Dereje N, Gebremariam A, Addissie A, et al. Factors associated with advanced stage at diagnosis of cervical cancer in Addis Ababa, Ethiopia: a population-based study. BMJ open. 2020;10(10):e040645. doi:10.1136/bmjopen-2020-040645
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer key facts [Internet]; 2020. Available from: http://www.who.int/news-room/fact-sheets/detail/cancer. Accessed June 7, 2022.
   Google Scholar
• Cancer Research UK. Worldwide cancer statistics [Internet]; 2020. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer. Accessed June 7, 2022.
   Google Scholar
• Aweke YH, Ayanto SY, Ersado TL. Knowledge, attitude and practice for cervical cancer prevention and control among women of childbearing age in Hossana Town, Hadiya zone, Southern Ethiopia: community-based cross-sectional study. PLoS One. 2017;12(7):e0181415. doi:10.1371/journal.pone.0181415
   PubMed Web of Science ®Google Scholar
• Getahun F, Mazengia F, Abuhay M, Birhanu Z. Comprehensive knowledge about cervical cancer is low among women in Northwest Ethiopia. BMC Cancer. 2013;13(1):1–7. doi:10.1186/1471-2407-13-2
   PubMed Web of Science ®Google Scholar
• Birhanu Z, Abdissa A, Belachew T, et al. Health seeking behavior for cervical cancer in Ethiopia: a qualitative study. Int J Equity Health. 2012;11(1):1–8. doi:10.1186/1475-9276-11-83
   PubMed Web of Science ®Google Scholar
• Zeleke S, Anley M, Kefale D, Wassihun B. Factors associated with delayed diagnosis of cervical cancer in tikur anbesa specialized hospital, Ethiopia, 2019: cross-Sectional Study. Cancer Manag Res. 2021;13:579. doi:10.2147/CMAR.S285621
   PubMed Web of Science ®Google Scholar
• Hailu A, Mariam DH. Patient side cost and its predictors for cervical cancer in Ethiopia: a cross sectional hospital based study. BMC Cancer. 2013;13(1):1–8. doi:10.1186/1471-2407-13-69
   PubMed Web of Science ®Google Scholar
• Jennifer M, Sturpe DA, Khanna N. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists. J Am Pharm Assoc. 2008;48(1):e1–e16. doi:10.1331/JAPhA.2008.07032
   Google Scholar
• Brewer NT, Chung JK, Baker HM, Rothholz MC, Smith JS. Pharmacist authority to provide HPV vaccine: novel partners in cervical cancer prevention. Gynecol Oncol. 2014;132:S3–S8. doi:10.1016/j.ygyno.2013.12.020
   PubMed Web of Science ®Google Scholar
• Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health. 2020;8(2):e191–e203. doi:10.1016/S2214-109X(19)30482-6
   PubMed Web of Science ®Google Scholar
• Wassie M, Aemro A, Fentie B. Prevalence and associated factors of baseline anemia among cervical cancer patients in Tikur Anbesa Specialized Hospital, Ethiopia. BMC Womens Health. 2021;21(1):1–8. doi:10.1186/s12905-020-01152-w
   PubMed Web of Science ®Google Scholar
• Chen CP, Kung PT, Wang YH, Tsai WC. Effect of time interval from diagnosis to treatment for cervical cancer on survival: a nationwide cohort study. PLoS One. 2019;14(9):e0221946. doi:10.1371/journal.pone.0221946
   PubMed Web of Science ®Google Scholar
• Desta M, Getaneh T, Yeserah B, et al. Cervical cancer screening utilization and predictors among eligible women in Ethiopia: a systematic review and meta-analysis. PLoS One. 2021;16(11):e0259339. doi:10.1371/journal.pone.0259339
   PubMed Web of Science ®Google Scholar
• Yismaw MB, Adam H, Engidawork E. Identification and resolution of drug-related problems among childhood cancer patients in Ethiopia. J Oncol. 2020;2020. doi:10.1155/2020/6785835
   PubMed Web of Science ®Google Scholar
• Mustapha S, Mohammed M, Mustapha L, Yunusa I, Basgut B. A survey on drug related problems in cervical cancer patients receiving chemotherapy in ahmadu bello university teaching hospital zaria. Bayero J Pure Appl Sci. 2017;10(1):489–492. doi:10.4314/bajopas.v10i1.93S
   Google Scholar
• Bekele F, Tsegaye T, Negash E, Fekadu G. Magnitude and determinants of drug-related problems among patients admitted to medical wards of southwestern Ethiopian hospitals: a multicenter prospective observational study. PLoS One. 2021;16(3):e0248575. doi:10.1371/journal.pone.0248575
   PubMed Web of Science ®Google Scholar
• Su YJ, Yan YD, Wang WJ, et al. Drug-related problems among hospitalized cancer pain patients: an investigative single-arm intervention trial. Annals of Palliative Medicine; 2020.
   Google Scholar
• Percie du Sert N, Rudd JA, Apfel CC, Andrews PLR. Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT3 receptor antagonists. Cancer Chemother Pharmacol. 2011;67(3):667–686. doi:10.1007/s00280-010-1339-4
   PubMed Web of Science ®Google Scholar
• Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266–272. doi:10.18433/J35C7Z
   PubMed Web of Science ®Google Scholar
• Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41(2):192–199. doi:10.1016/S1086-5802(16)31229-3
   Google Scholar
• Cohen IV, Makunts T, Abagyan R, Thomas K. Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Sci Rep. 2021;11(1):1–9. doi:10.1038/s41598-021-85389-x
   PubMed Web of Science ®Google Scholar